	Capitaux Propres Et Réserves		Date
AbbVie	USD -3.27B	628M	2025-12
Agios Pharmaceuticals	USD 1.19B	91.22M	2025-12
ALKERMES	USD 1.82B	85.86M	2025-12
Alnylam Pharmaceuticals	USD 789.18M	555.28M	2025-12
Amgen	USD 8.66B	961M	2025-12
Biogen	USD 18.21B	573.5M	2025-09
BioMarin Pharmaceutical	USD 6.09B	30.29M	2025-12
Bristol-Myers Squibb	USD 18.55B	1.06B	2025-09
Coherus Biosciences	USD 87.77M	32.05M	2025-09
Eli Lilly	USD 26.54B	2.74B	2025-12
Gilead Sciences	USD 22.62B	1.16B	2025-12
GlaxoSmithKline	GBP 16.38B	229M	2025-12
Glaxosmithkline	GBP 21.7B	7.35B	2025-09
Incyte	USD 5.17B	516.28M	2025-12
J&J	USD 78.47B	0	2025-09
Merck	USD 51.85B	2.79B	2025-09
Moderna	USD 8.65B	680M	2025-12
Neurocrine Biosciences	USD 3.25B	249.5M	2025-12
Novartis	USD 44.75B	2.7B	2025-09
Pfizer	USD 92.8B	4.11B	2025-09
PTC Therapeutics	USD -205.31M	49.56M	2025-12
Puma Biotechnology	USD 115.27M	10.55M	2025-09
Regeneron Pharmaceuticals	USD 31.26B	299.1M	2025-12
Sangamo BioSciences	USD 19.6M	14.7M	2025-06
Sanofi	EUR 71.71B	1.55B	2025-12
Sarepta Therapeutics	USD 1.14B	179.5M	2025-12
United Therapeutics	USD 7.1B	506M	2025-12
Vertex Pharmaceuticals	USD 18.67B	1.35B	2025-12

Gilead Sciences Capitaux Propres Et Réserves - Les valeurs actuelles, des données historiques, des prévisions, des statistiques, des tableaux et le calendrier économique - Feb 2026.